Literature DB >> 2456259

Aberrant production and regulation of proopiomelanocortin-derived peptides in ectopic Cushing's syndrome.

K A Roth1, D C Newell, R I Dorin, J H Eberwine, A R Hoffman.   

Abstract

A 64 year old woman with a pancreatic islet cell tumor developed Cushing's syndrome. Glucocorticoid secretion did not decrease after low or high dose dexamethasone administration, and the Cushing's syndrome was cured by removal of tumor tissue. Immunohistochemistry and radioimmunoassays revealed the presence of immunoreactive ACTH, beta-endorphin and alpha-MSH in the tumor cells. Gel-permeation chromatography confirmed that beta-endorphin was the predominant opioid peptide produced by the tumor. The tumor was shown to contain a single 1.2 kilobase RNA species which hybridized to a 32P human POMC-cDNA; this POMC RNA was identical in size to that isolated from a normal human pituitary. In dispersed monolayer culture, CRF failed to elicit ACTH release from the tumor cells, but dexamethasone caused a paradoxical increase in ACTH secretion in vitro. This study demonstrates that aberrant regulation of POMC synthesis and peptide processing can be seen in tumors which synthesize a POMC RNA identical in size to that made in the pituitary gland.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2456259     DOI: 10.1055/s-2007-1010799

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  2 in total

1.  A case of pseudo-Nelson's syndrome: cure of ACTH hypersecretion by removal of a bronchial carcinoid tumor responsible for Cushing's syndrome.

Authors:  J D Lalau; D Vieau; F Tenenbaum; P F Westeel; A Mesmacque; F Lenne; J Quichaud
Journal:  J Endocrinol Invest       Date:  1990-06       Impact factor: 4.256

2.  Evaluation of proopiomelanocortin mRNA in the peripheral blood from patients with Cushing's syndrome of different origin.

Authors:  S Bondioni; G Mantovani; N Polentarutti; B Ambrosi; P Loli; E Peverelli; A G Lania; P Beck-Peccoz; A Spada
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.